Are you over 18 and want to see adult content?
More Annotations
A complete backup of hausheimgarten.com
Are you over 18 and want to see adult content?
A complete backup of murphysicecream.ie
Are you over 18 and want to see adult content?
A complete backup of fredperrysverige.nu
Are you over 18 and want to see adult content?
A complete backup of yogicentral.science
Are you over 18 and want to see adult content?
A complete backup of authoritypresswire.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://coastalplain.com
Are you over 18 and want to see adult content?
A complete backup of https://lodenfrey.com
Are you over 18 and want to see adult content?
A complete backup of https://birzha-othodov.ru
Are you over 18 and want to see adult content?
A complete backup of https://faiservice.it
Are you over 18 and want to see adult content?
A complete backup of https://hsselite.com
Are you over 18 and want to see adult content?
A complete backup of https://henokahmed.com
Are you over 18 and want to see adult content?
A complete backup of https://michael-martin.de
Are you over 18 and want to see adult content?
A complete backup of https://filasolutions.com
Are you over 18 and want to see adult content?
A complete backup of https://megt.com.au
Are you over 18 and want to see adult content?
A complete backup of https://coopertino.ru
Are you over 18 and want to see adult content?
A complete backup of https://vickiarcher.com
Are you over 18 and want to see adult content?
A complete backup of https://hollisbrown.com
Are you over 18 and want to see adult content?
Text
AGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- X-LINKED RETINITIS PIGMENTOSA Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother to her children resulting in a form of RP known as X-Linked RP (XLRP).AGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- X-LINKED RETINITIS PIGMENTOSA Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother to her children resulting in a form of RP known as X-Linked RP (XLRP).PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareABOUT - AGTC
Dr. Feinsod served as AGTC’s Chief Medical Officer from 2017 to 2019, leading our 4 ongoing clinical trials in inherited retinal diseases. He is a board-certified ophthalmologist with extensive corporate, clinical and regulatory expertise in the development of novel therapies for ophthalmic diseases.OUR COMMITMENT
As part of our commitment to learning from patients and families, AGTC has established a Patient Advisory Council made up of individuals with inherited retinal diseases (IRDs) and leaders of the organizations that represent them. The council provides valuable insights about the unique journey and experiences of living with IRDs.BIONIC SIGHT
AGTC is investing and partnering in Bionic Sight’s development of an optogenetic therapy. This innovative approach combines gene delivery technology with a device developed by Dr. Sheila Nirenberg, founder of Bionic Sight and a professor at the Weill Medical College AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- AGTC PRESENTS DATA DEMONSTRATING EFFICIENCY OF ITS AAV October 21, 2019 at 7:00 AM EDTPDF Version –Data support safety and potential clinical utility of AGTC’s ocular gene therapy candidates regardless of patients’ AAV antibody status- GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associatedACHROMATOPSIA
Achromatopsia (ACHM) is an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes. ACHM is associated with extremely poor visual acuity (most affected individuals are legally blind), extreme light sensitivity resulting in daytime blindness, and complete loss of color discrimination. 0001193125-19-255968 The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts. AGTC ANNOUNCES DATA EVALUATING NOVEL AAV-BASED GENE GAINESVILLE, Fla. and CAMBRIDGE, Mass. and PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating the use of recombinant AAV-AAT vector geneAGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- X-LINKED RETINITIS PIGMENTOSA Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother to her children resulting in a form of RP known as X-Linked RP (XLRP).AGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- X-LINKED RETINITIS PIGMENTOSA Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother to her children resulting in a form of RP known as X-Linked RP (XLRP).PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareABOUT - AGTC
Dr. Feinsod served as AGTC’s Chief Medical Officer from 2017 to 2019, leading our 4 ongoing clinical trials in inherited retinal diseases. He is a board-certified ophthalmologist with extensive corporate, clinical and regulatory expertise in the development of novel therapies for ophthalmic diseases.OUR COMMITMENT
As part of our commitment to learning from patients and families, AGTC has established a Patient Advisory Council made up of individuals with inherited retinal diseases (IRDs) and leaders of the organizations that represent them. The council provides valuable insights about the unique journey and experiences of living with IRDs.BIONIC SIGHT
AGTC is investing and partnering in Bionic Sight’s development of an optogenetic therapy. This innovative approach combines gene delivery technology with a device developed by Dr. Sheila Nirenberg, founder of Bionic Sight and a professor at the Weill Medical College AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- AGTC PRESENTS DATA DEMONSTRATING EFFICIENCY OF ITS AAV October 21, 2019 at 7:00 AM EDTPDF Version –Data support safety and potential clinical utility of AGTC’s ocular gene therapy candidates regardless of patients’ AAV antibody status- GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associatedACHROMATOPSIA
Achromatopsia (ACHM) is an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes. ACHM is associated with extremely poor visual acuity (most affected individuals are legally blind), extreme light sensitivity resulting in daytime blindness, and complete loss of color discrimination. 0001193125-19-255968 The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts. AGTC ANNOUNCES DATA EVALUATING NOVEL AAV-BASED GENE GAINESVILLE, Fla. and CAMBRIDGE, Mass. and PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating the use of recombinant AAV-AAT vector geneAGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- X-LINKED RETINITIS PIGMENTOSA Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother to her children resulting in a form of RP known as X-Linked RP (XLRP).AGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- X-LINKED RETINITIS PIGMENTOSA Retinitis pigmentosa (RP) describes a group of rare genetic eye diseases that damage light-sensitive cells in the retina, leading to loss of sight over time. In about 10% of RP cases, the non-working gene is passed down from the mother to her children resulting in a form of RP known as X-Linked RP (XLRP).PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rareABOUT - AGTC
Dr. Feinsod served as AGTC’s Chief Medical Officer from 2017 to 2019, leading our 4 ongoing clinical trials in inherited retinal diseases. He is a board-certified ophthalmologist with extensive corporate, clinical and regulatory expertise in the development of novel therapies for ophthalmic diseases.OUR COMMITMENT
As part of our commitment to learning from patients and families, AGTC has established a Patient Advisory Council made up of individuals with inherited retinal diseases (IRDs) and leaders of the organizations that represent them. The council provides valuable insights about the unique journey and experiences of living with IRDs.BIONIC SIGHT
AGTC is investing and partnering in Bionic Sight’s development of an optogenetic therapy. This innovative approach combines gene delivery technology with a device developed by Dr. Sheila Nirenberg, founder of Bionic Sight and a professor at the Weill Medical College AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
AGTC REPORTS POSITIVE 12-MONTH DATA FROM HIGHEST DOSE -Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials--Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- AGTC PRESENTS DATA DEMONSTRATING EFFICIENCY OF ITS AAV October 21, 2019 at 7:00 AM EDTPDF Version –Data support safety and potential clinical utility of AGTC’s ocular gene therapy candidates regardless of patients’ AAV antibody status- GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associatedACHROMATOPSIA
Achromatopsia (ACHM) is an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes. ACHM is associated with extremely poor visual acuity (most affected individuals are legally blind), extreme light sensitivity resulting in daytime blindness, and complete loss of color discrimination. 0001193125-19-255968 The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts. AGTC ANNOUNCES DATA EVALUATING NOVEL AAV-BASED GENE GAINESVILLE, Fla. and CAMBRIDGE, Mass. and PHILADELPHIA, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating the use of recombinant AAV-AAT vector geneAGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 ClinicaPIPELINE - AGTC
The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase2/3 Trial
AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - AGTC TO PRESENT AT THE 4TH ANNUAL GENE THERAPY FOR RARE The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts.AGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
NEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 ClinicaPIPELINE - AGTC
The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase2/3 Trial
AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - AGTC TO PRESENT AT THE 4TH ANNUAL GENE THERAPY FOR RARE The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts.PIPELINE - AGTC
The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments forCAREERS - AGTC
AGTC is an equal opportunity employer and maintains a drug free environment. Competitive compensation is offered commensurate with education and experience. AGTC TO PRESENT AT THE 4TH ANNUAL GENE THERAPY FOR RARE The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts. NON-SYNDROMIC HEARING LOSS AND DEAFNESS Non-syndromic hearing loss and deafness (DFNB1) is an autosomal recessive disorder characterized by congenital non-progressive mild-to-profound sensorineural hearing impairment. DFNB1 is the most common form of genetic hearing loss, accounting for nearly 30% of allcases.
AGTC ANNOUNCES NEW LEADERSHIP APPOINTMENTS Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join AGTC as Chief Medical Officer Brian Krex Named General Counsel . GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene EVENTS & PRESENTATIONS The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts.SEC FILINGS
The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts. AGTC ANNOUNCES TOPLINE INTERIM SIX-MONTH DATA FROM PHASE 1 The Investor Relations website contains information about Applied Genetic Technologies Corporation's business for stockholders, potential investors, and financial analysts. AGTC PRESENTS NEW DATA ON ITS AAV-BASED GENE THERAPIES FOR AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting 23.9 KB AGTC APPOINTS WILLIAM SULLIVAN AS CHIEF FINANCIAL OFFICER GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointments of William Sullivan to the position of Chief Financial Officer and AndrewAGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rare AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - EVENTS & PRESENTATIONS Listen to webcast. XLRP Data Summary – Month 12 High Dose Groups. 2.1 MB. Apr 6 - Apr 9, 2021. Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean. Listen to webcast. Mar 24, 2021 at 8:30 AM EDT. Gene Therapy Patient Engagement Summit. Mar 15, 2021 at1:00 PM EDT.
AGTC PRESENTS NEW DATA ON ITS AAV-BASED GENE THERAPIES FOR AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting 23.9 KBAGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rare AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - EVENTS & PRESENTATIONS Listen to webcast. XLRP Data Summary – Month 12 High Dose Groups. 2.1 MB. Apr 6 - Apr 9, 2021. Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean. Listen to webcast. Mar 24, 2021 at 8:30 AM EDT. Gene Therapy Patient Engagement Summit. Mar 15, 2021 at1:00 PM EDT.
AGTC PRESENTS NEW DATA ON ITS AAV-BASED GENE THERAPIES FOR AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting 23.9 KBNEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.ABOUT - AGTC
Dr. Feinsod served as AGTC’s Chief Medical Officer from 2017 to 2019, leading our 4 ongoing clinical trials in inherited retinal diseases. He is a board-certified ophthalmologist with extensive corporate, clinical and regulatory expertise in the development of novel therapies for ophthalmic diseases. AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
OUR COMMITMENT
As part of our commitment to learning from patients and families, AGTC has established a Patient Advisory Council made up of individuals with inherited retinal diseases (IRDs) and leaders of the organizations that represent them. The council provides valuable insights about the unique journey and experiences of living with IRDs.BIONIC SIGHT
AGTC is investing and partnering in Bionic Sight’s development of an optogenetic therapy. This innovative approach combines gene delivery technology with a device developed by Dr. Sheila Nirenberg, founder of Bionic Sight and a professor at the Weill Medical CollegeCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC APPOINTS MICHAEL GOLDSTEIN, M.D. AS CHIEF MEDICAL GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointment of Michael Goldstein, M.D., M.B.A. as Chief Medical Officer (CMO)AGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rare AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - EVENTS & PRESENTATIONS Listen to webcast. XLRP Data Summary – Month 12 High Dose Groups. 2.1 MB. Apr 6 - Apr 9, 2021. Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean. Listen to webcast. Mar 24, 2021 at 8:30 AM EDT. Gene Therapy Patient Engagement Summit. Mar 15, 2021 at1:00 PM EDT.
AGTC PRESENTS NEW DATA ON ITS AAV-BASED GENE THERAPIES FOR AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting 23.9 KBAGTC - DEVELOPING
GROUNDBREAKINGABOUTPROGRAMSSCIENCEPATIENTSCAREERSINVESTORS Latest AGTC News. AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica; AGTC Announces NewInitiatives To
PIPELINE - AGTC
Programs & Pipeline. The answer to genetic blindness begins with a CLEAR VISION - AGTC’s clinical trials are research studies that are exploring potentially life-changing treatments for rare genetic eye disorders, including XLRP and achromatopsia. We are focused on genetic therapies that can restore visual function in patients with rare AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
AGTC ANNOUNCES EXPANSION OF MANUFACTURING AND ANALYTICS - Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules -. GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology AGTC PROVIDES TRIAL DESIGN UPDATE FOR ITS PHASE 2/3 XLRP AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020 AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today INVESTORS | APPLIED GENETIC TECHNOLOGIES CORPORATION Investors. Investors. AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - EVENTS & PRESENTATIONS Listen to webcast. XLRP Data Summary – Month 12 High Dose Groups. 2.1 MB. Apr 6 - Apr 9, 2021. Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean. Listen to webcast. Mar 24, 2021 at 8:30 AM EDT. Gene Therapy Patient Engagement Summit. Mar 15, 2021 at1:00 PM EDT.
AGTC PRESENTS NEW DATA ON ITS AAV-BASED GENE THERAPIES FOR AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting 23.9 KBNEWS - AGTC
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica. March 30, 2021.ABOUT - AGTC
Dr. Feinsod served as AGTC’s Chief Medical Officer from 2017 to 2019, leading our 4 ongoing clinical trials in inherited retinal diseases. He is a board-certified ophthalmologist with extensive corporate, clinical and regulatory expertise in the development of novel therapies for ophthalmic diseases. AGTC ANNOUNCES UPDATED DEVELOPMENT PLAN FOR ITS X-LINKED AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial. July 22, 2020 at 7:00 AM EDT PDF Version. Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinicaldevelopment.
OUR COMMITMENT
As part of our commitment to learning from patients and families, AGTC has established a Patient Advisory Council made up of individuals with inherited retinal diseases (IRDs) and leaders of the organizations that represent them. The council provides valuable insights about the unique journey and experiences of living with IRDs.BIONIC SIGHT
AGTC is investing and partnering in Bionic Sight’s development of an optogenetic therapy. This innovative approach combines gene delivery technology with a device developed by Dr. Sheila Nirenberg, founder of Bionic Sight and a professor at the Weill Medical CollegeCAREERS - AGTC
Check out our open positions below to join the team! We are committed to transparency. We foster a data-driven and goal oriented work environment where project leadership is encouraged at all levels. At AGTC we believe in a work hard, play hard philosophy. We bring together industry-leading experts and innovative thinkers to create an AGTC ANNOUNCES SIGNIFICANT PRODUCTIVITY AND QUALITY Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials. GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today AGTC ANNOUNCES PUBLICATION OF POSITIVE PRECLINICAL DATA - Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - AGTC TO HOST THIRD QUARTER FINANCIAL RESULTS CONFERENCE GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after AGTC APPOINTS MICHAEL GOLDSTEIN, M.D. AS CHIEF MEDICAL GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointment of Michael Goldstein, M.D., M.B.A. as Chief Medical Officer (CMO)* About
* Our Team
* Board of Directors * Scientific Advisors* Collaborations
* Pipeline
* Programs and Pipeline* Optogenetics
* Age-Related Macular Degeneration * Non-syndromic hearing loss and deafness* Science
* Science & Technology * Publications and Presentations* Clinical Trials
* X-Linked Retinitis Pigmentosa* Achromatopsia
* Patients
* Our Commitment
* Patient Advocacy
* Gene Therapy
* Patient Resources
* Careers
* Investors
* Say Hello
Size A A Color C C C C __ ListenReadSpeaker webReader: ListenOpen/close
toolbarFocus
* About
* Our Team
* Board of Directors * Scientific Advisors* Collaborations
* Pipeline
* Programs and Pipeline* Optogenetics
* Age-Related Macular Degeneration * Non-syndromic hearing loss and deafness* Science
* Science & Technology * Publications and Presentations* Clinical Trials
* X-Linked Retinitis Pigmentosa* Achromatopsia
* Patients
* Our Commitment
* Patient Advocacy
* Gene Therapy
* Patient Resources
* Careers
* Investors
* Say Hello
DEVELOPING GROUNDBREAKING GENE THERAPIES FOR PATIENTS WITH RARE DISEASES. With the patient in mind WE DESIGN TREATMENTS JUST FOR YOU. At AGTC we are developing genetic therapies to treat patients with rare inherited conditions. Our most advanced therapy programs are designed to restore visual function and meet the needs of patients with rare blinding conditions.Learn more
LATEST AGTC NEWS
* AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica * AGTC Announces New Initiatives To Enhance The Patient Journey InIts XLRP Trials
* AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020View All News
OUR PROGRAMS
AT AGTC WE ARE FOCUSED ON GENETIC THERAPIES THAT CAN RESTORE VISUAL FUNCTION IN PATIENTS WITH RARE INHERITED CONDITIONS. At AGTC we are focused on genetic therapies that can restore visual function in patients with rare inherited conditions. Simple activities such as riding a bike, playing outside, and even the ability to recognize a loved one in a crowd, can be impossible for patients with rare blinding conditions. Our treatment candidates have the potential to dramatically improve visual function in patients with conditions where only palliative or no therapies exist today.our programs
* 1Achromatopsia
* 2Optogenetics
* 3X-Linked Retinitis Pigmentosa * 4Age-Related Macular Degeneration GENE THERAPY AT ITS FINEST GENETIC THERAPIES ARE COMPLEX, WITH INTERDEPENDENT COMPONENTS THAT MUST WORK IN HARMONY. Fifteen years of gene therapy experience allows us at AGTC to design and construct all critical gene therapy elements and bring them together to develop successful treatments for patients.* Capsid Diversity
* Formulation
* Gene Cassette
* Manufacturing
* Promoter
* Vector Administration Visionary science for life changing cures. Contact us Join our team* About
* Our Team
* Board of Directors* Collaborations
* Scientific Advisors* News
* Pipeline
* Achromatopsia
* X-Linked Retinitis Pigmentosa* Optogenetics
* Age-Related Macular Degeneration* Technology
* Gene Therapy
* AAV
* Orphan Indications* Our Commitment
* Patient Advocacy
* Patient Resources
* Careers
* Open Positions
* Our Culture
* Investors
* Overview
* Financials
* Stock Information
* Investor FAQ’s
* Ethics and Compliance © agtc. All rights reserved.__
__ __
__
×
CONTACT US
I am a...PatientCaregiverHealthcare ProviderOther×
HEALTHCARE PROFESSIONALS*
*
*
I am a...OphthalmologistIRD SpecialistVitreoretinal surgeonOptometristGeneticistPrimary Care ProviderOther Does the individual with XLRP currently live in the US?YesNo Is the individual with XRLP between the age of 8 and 50?YesNoI don’tknow
Do you have the medical, genetic test results, or ophthalmology records of the individual with XLRP?YesNoOther Has the person with XLRP (or one of their family members) received genetic testing to confirm a mutation in the RPGR gene?YesNoI don’tknow
How did you learn about the trial (check all that apply): BluePrint GeneticscommunicationFoundation Fighting BlindnessFighting Blindness CanadaClinicaltrials.govInternet ad or social mediaOther×
PATIENTS-CAREGIVERS FORM I am a...Person with XLRP who has a confirmed mutation in the RPGR genePerson with RP who has not received genetic testing to confirm my mutationFamily or caregiver of person with XLRPOther*
Has the person with XLRP (or one of their family members) received genetic testing to confirm a mutation in the RPGR gene?YesNoI don’tknow
*
*
*
*
*
Does the individual with XLRP currently live in the US?YesNo*
*
*
Is the individual with XRLP between the age of 8 and 50?YesNoIdon’t know
*
How did you learn about the trial (check all that apply): BluePrint GeneticscommunicationFoundation Fighting BlindnessFighting Blindness CanadaClinicaltrials.govInternet ad or social mediaOtherDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0